In patients already receiving incretin-based therapy for diabetes/obesity who still have NITs suggesting persistent F2–F3 disease, what clinical signals or NIT patterns lead you to prioritize (1) optimizing anti-obesity incretin dosing, (2) switching incretin class, or (3) adding a thyroid hormone receptor-β agonist for MASH?
Community PollStarted
What do you prioritize for patients on incretins for diabetes/obesity whose NITs still suggest F2-F3 MASH?
2 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Hepatology · Mayo Clinic
Answered on
If they are already receiving it, ensure doses have been escalated for weight loss (many DM doses don’t get escalated if their sugars stabilize) by their local team. If they are on a full dose, I would add Rezdiffra if insurance will cover it. Or I get them into a study (can access if weight is stab...
Join for free or sign in to see the full answer